Vaccibody

View in Terminal

Loading quotes...

Forecast

There is no analyst data available for this company.

News Go to news feed

There is currently no news available for this company. We are working on adding more providers to change this.

Historical dividends Dividends

All dividend metrics All metrics

In 2025, Vaccibody has already paid €0.0869 in dividends. The last payout was in June 2025.

Financials

In the last quarter, Vaccibody had revenue of €92.88k and net profit of -€6.3m

(EUR)	June 2026	YoY
Revenue	92.88k	44.71%
Gross profit	92.88k	44.71%
Net profit	-6.3m	963.83%
EBITDA	-5.65m	946.16%

Fundamentals

Metric	Value
Market capitalization	€113.06m
Number of shares	391.55m
52-week high/low	€0.50 - €0.20
Dividends	No
Beta	0.86
P/E ratio	-4.68
PEG ratio	0.08
P/B ratio	1.32
P/S ratio	1,205.34

Company profile

Nykode Therapeutics AS, a clinical-stage biopharmaceutical company, discovers and develops novel immunotherapies. The company develops vaccines for the treatment cancer and infectious diseases. Its lead product candidates include VB10.NEO, a cancer neoantigen vaccine, which is in phase I/IIa clinical trial for the treatment of ,melanoma, lung, bladder, renal, head, and neck cancer; VB10.16, a therapeutic vaccine, which in phase II clinical trial for the treatment of human papilloma virus 16 induced malignancies, such as cervical cancer; and VB10. COV2, a COVID-19 vaccine candidate covers new SARS-CoV-2 variants. The company has collaboration agreements with Roche, Genentech, MSD, and Nektar Therapeutics; Adaptive Biotechnologies for COVID-19 T cell vaccine development; and research agreement with Regeneron. The company was formerly known as Vaccibody AS. Nykode Therapeutics AS was founded in 2006 and is based in Oslo, Norway.